Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
Status:
Recruiting
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone
receptor positive, HER2 negative, node negative breast cancer in women older than 50 at
diagnosis.
The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a
population with low risk of breast cancer; as determined by histopathologic criteria and
confirmed by low risk genomic analysis using Prosigna®; will be safe and acceptable to this
population, and will not compromise the expected excellent breast cancer specific outcomes
for this population.
Phase:
Phase 2
Details
Lead Sponsor:
British Columbia Cancer Agency
Collaborators:
Canadian Cancer Society (CCS) Canadian Cancer Society Research Institute (CCSRI) NanoString Technologies, Inc.